Article in Science immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors at 5 institutions in 3 countries.
William H PalmerDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0002-0348-6339
Laura Ann LeatonDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0002-0650-5830
Ana Campos CodoDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0001-9036-5772
Bergren CruteDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0002-6179-3708
James RoestInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0003-0781-7403
Shiying ZhuInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Jan PetersenInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-2045-6342
Richard P TobinDepartment of Surgery, Division of Surgical Oncology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0003-3890-4534
Patrick S HumeDepartment of Medicine, National Jewish Health, Denver, CO, USA.ORCID 0000-0002-5861-7375
Matthew StoneDepartment of Surgery, Division of Surgical Oncology, University of Colorado School of Medicine, Aurora, CO, USA.
Adrie van BokhovenDepartment of Pathology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0002-6059-2429
Mark E GerichDivision of Gastroenterology and Hepatology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0009-0008-1952-1486
Martin D McCarterDepartment of Surgery, Division of Surgical Oncology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0001-8174-1713
Yuwen ZhuDepartment of Surgery, Division of Surgical Oncology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0003-1434-6590
William J JanssenDepartment of Medicine, National Jewish Health, Denver, CO, USA.ORCID 0000-0002-6397-3454
Julian P VivianInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-9400-4437
Andrew GetahunDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Jamie RossjohnInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-2020-7522
John CambierDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0002-7803-242X
Liyen LohDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0002-1676-0579
Paul J NormanDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0001-8370-7703
University of Colorado Denver · USAustralian Regenerative Medicine Institute · AUNational Jewish Health · USThe University of Melbourne · AUUniversity of Cambridge · GB
Funding
NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI JANE E REUSCH · 2020 to 2026
$10.8M
TRAINING PROGRAM IN IMMUNOLOGYT32AI007405 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Laurel L Lenz, Raul Martin Torres · 1991 to 2026
$10.5M
Lung Macrophage Programming in Acute Lung InjuryR35HL140039 · NHLBI · NATIONAL JEWISH HEALTH · PI JANSSEN, WILLIAM · 2018 to 2024
$6.4M
Mechanisms of lung macrophage programming by MUC5B during health and diseaseR01HL130938 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI EVANS, CHRISTOPHER M · 2016 to 2025
$5.2M
Roles for interstitial and airspace macrophages in resolution of pulmonary inflammationR01HL149741 · NHLBI · NATIONAL JEWISH HEALTH · PI HENSON, PETER M, REDENTE, ELIZABETH FRANCES · 2020 to 2023
$3.0M
Interstitial macrophages in cigarette smoke-induced small airway remodelingK08HL155894 · NHLBI · NATIONAL JEWISH HEALTH · PI Patrick Scott Hume · 2022 to 2026
$792k
Control of Cytotoxic Lymphocytes by Polymorphic KIR3DL3R56AI155729 · NIAID · UNIVERSITY OF COLORADO DENVER · PI NORMAN, PAUL JOHN · 2021 to 2021
$360k
Variable natural killer cell responses in the control of Epstein-Barr virus infectionF32AI161790 · NIAID · UNIVERSITY OF COLORADO DENVER · PI PALMER, WILLIAM HUNT · 2022 to 2022
Most human killer cell immunoglobulin-like receptors (KIR) are expressed by natural killer (NK) cells and recognize HLA class I molecules as ligands. KIR3DL3 is a conserved but polymorphic inhibitory KIR recognizing a B7 family ligand, HHLA2, and is implicated for immune checkpoint targeting. The expression profile and biological function of KIR3DL3 have been somewhat elusive, so we searched extensively for KIR3DL3 transcripts, revealing highly enriched expression in γδ and CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.